# PantoCIN newsletter



Issue 02, August 2019

Welcome to.... Wellington Regional Hospital, Waikato Hospital, Rotorua Hospital, Auckland City Hospital and Christchurch Hospital ...who are now open to recruitment!

### Background

PantoCIN is a phase II, randomised, double-blinded, placebo controlled, crossover trial to assess Pantoprazole's effectiveness as prophylaxis against delayed Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy. The study will recruit **160 patients** from sites across New Zealand. It is managed by Cancer Trials New Zealand and funded by:



PantoCIN is a PRO study! This study depends on PRO data.

Tips to help ensure PRO data compliance:

#### Discuss upcoming questionnaire dates...

with the patient (see protocol section 7.1) write the dates down or on the questionnaires in advance, as required

#### Bookmark...

website www.HealthObs.com/PantoCin

**Download the app ...**with the patient (use the instructions in your site file) and demonstrate it with the patient.


## PantoCIN dataset: source data

#### Do you have a source data form or a helpful tip you'd like to share? Send to us for inclusion in the next newsletter

At CTNZ, we have an electronic/paper copy of all the data fields for PantoCIN, this can be used as a **source data template**, for participants on the study, and to ensure all data fields are collected. If you would like your hospital header/footer added to the document, then contact us.

### Recruitment

Well done to the PantoCIN teams at Rotorua Hospital, Tauranga hospital, Wellington Regional Hospital and Auckland City Hospital, leading the way with two recruits each! Keep up the good work! We need 160 patients for the PantoCIN study. It would be great to see all sites recruit in August! Below is a graph of actual and expected recruitment:



#### Recruitment by site

Rotorua Hospital2Tauranga Hospital2Wellington Regional Hospital2Auckland City Hospital2Palmerston North Hospital1Waikato Hospital0Christchurch Hospital0


## Screening logs

Please keep your screening logs up to date, as we will request copies of these periodically. A copy of the log is in section 10 of your Investigator Site file; refer to Study Procedure 004 (ISF, section 13), for guidance on screening for PantoCIN.










1) Log in first to EDC entering screening and participant contact and only go to randomisation using the participant number given in the EDC. Once participant is randomised, treatment should start within 3 days

2) Ensure that the participant completes the baseline questionnaires and remind them about the importance of the compliance to study drug and questionnaires in cycle 1.



#### PantoCIN teleconference

#### Next teleconference is Wednesday 28 August

This is open to all PantoCIN Team members at participating sites and provides an opportunity to ask questions or discuss any aspect of the trial with the PantoCIN Team at CTNZ and to share experiences of the trial with other sites. We recommend you participate in these teleconferences.



Date for your diary... Join us at CTNZ Annual Scientific Meeting 24 October 2019, Wellington Contact us for more details

# PantoCIN on Twitter!

## News from Twitter @CancerTrialsNZ follow us for PantoCIN updates!



#### Contact us

For general trial management queries please contact us:

Louise.clement@auckland.ac.nz Tel: 09 923 4626 Fax: 09 373 7927 www.cancertrialsnz.ac.nz



PantoCIN: Pantoprazole for delayed CINV Ethics ref. 18 / CEN / 224 NCT 03948477





CancerTrials New Zealand